1. Show article details.

    Expert Ratings for Intellia Therapeutics

    Benzinga – 11:09 AM ET 08/05/2022

    Within the last quarter, Intellia Therapeutics has observed the following analyst ratings: In the last 3 months, 6 analysts have offered 12-month price targets for Intellia Therapeutics. Below is a summary of how these 6 analysts rated Intellia Therapeutics over the past 3 months.

  2. Show article details.

    Clorox, Crocs And Some Other Big Stocks Moving Lower On Thursday

    Benzinga – 2:02 PM ET 08/04/2022

      AMTD Digital Inc. dipped 43.6% to $620.00 on possible profit taking after the stock surged over the last few trading days.      

  3. Show article details.

    Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate

    Benzinga – 9:06 AM ET 08/04/2022

    Here's a roundup of top developments in the biotech space over the last 24 hours: The European Union has approved AstraZeneca Plc  and Merck & Co Inc's  Lynparza for human epidermal growth factor receptor 2-negative high-risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy.

  4. Show article details.

    Recap: Intellia Therapeutics Q2 Earnings

    Benzinga – 8:51 AM ET 08/04/2022

      Intellia Therapeutics reported its Q2 earnings results on Thursday, August 4, 2022 at 07:30 AM. Here's what investors need to know about the announcement. Intellia Therapeutics missed estimated earnings by 1.53%, reporting an EPS of $-1.33 versus an estimate of $-1.31. Revenue was up $7.48 million from the same period last year.

  5. Show article details.

    BRIEF-Intellia Therapeutics Says Net Loss Was $100.7 Mln For Q2

    Reuters – 7:57 AM ET 08/04/2022

    Intellia Therapeutics Inc (NTLA): * CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $906.9 MILLION AS OF JUNE 30, 2022. * NET LOSS WAS $100.7 MILLION FOR Q2 OF 2022, COMPARED TO $68.8 MILLION DURING Q2 OF 2021. * QTRLY NET LOSS PER SHARE, BASIC AND DILUTED$1.33. * Q2 EARNINGS PER SHARE VIEW $-1.31 -- REFINITIV IBES DATA Source text for Eikon: Further company coverage:

  6. Show article details.

    Intellia Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress

    GlobeNewswire – 7:30 AM ET 08/04/2022

    CAMBRIDGE, Mass., Aug. 04, 2022 -- Intellia Therapeutics, Inc. (NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today reported operational highlights and financial results for the second quarter ended June 30, 2022.

  7. Show article details.

    Earnings Scheduled For August 4, 2022

    Benzinga – 7:23 AM ET 08/04/2022

      ** Toyota Motor is projected to report earnings for its first quarter. ** Myriad Genetics is expected to report quarterly earnings at $0.01 per share on revenue of $171.00 million. ** Karyopharm Therapeutics is expected to report quarterly loss at $0.63 per share on revenue of $35.59 million.

  8. Show article details.

    Earnings Scheduled For August 4, 2022

    Benzinga – 4:23 AM ET 08/04/2022

      ** Toyota Motor is projected to report earnings for its first quarter. ** Myriad Genetics is expected to report quarterly earnings at $0.01 per share on revenue of $171.00 million. ** Karyopharm Therapeutics is expected to report quarterly loss at $0.63 per share on revenue of $35.59 million.

  9. Show article details.

    Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2022 Earnings and Company Updates

    GlobeNewswire – 7:30 AM ET 07/27/2022

    Intellia Therapeutics, Inc. (NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, will present its second quarter 2022 financial results and operational highlights in a conference call on August 4, 2022, at 8 a.m. ET.

  10. Show article details.

    10 Health Care Stocks With Whale Alerts In Today's Session

    Benzinga – 1:54 PM ET 07/20/2022

    This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often look for circumstances when the market estimation of an option diverges away from its normal worth.

  11. Show article details.

    Intellia's Gene-Editing Candidate Shows Durability In ATTR Amyloidosis

    Benzinga – 12:50 PM ET 06/24/2022

    Intellia's Gene-Editing Candidate Shows Durability In ATTR Amyloidosis

  12. Show article details.

    BRIEF-Intellia, Regeneron Present Interim Data From Phase 1 Study Of Crispr-Based NTLA-2001

    Reuters – 8:32 AM ET 06/24/2022

    Regeneron Pharmaceuticals Inc (REGN): * INTELLIA AND REGENERON PRESENT UPDATED INTERIM DATA FROM PHASE 1 STUDY OF CRISPR-BASED NTLA-2001 FOR THE TREATMENT OF TRANSTHYRETIN AMYLOIDOSIS DEMONSTRATING THAT DEEP SERUM TTR REDUCTIONS REMAINED DURABLE AFTER A SINGLE DOSE. * INTELLIA THERAPEUTICS INC (NTLA)- AT ALL FOUR DOSE LEVELS, NTLA-2001 WAS GENERALLY WELL TOLERATED THROUGH FOLLOW-UP PERIOD.

  13. Show article details.

    Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose

    PR Newswire – 7:31 AM ET 06/24/2022

    Serum TTR reductions were sustained at all doses tested with follow-up now reaching 12 months in the 0.1 and 0.3 mg/kg and six months in the 0.7 and 1.0 mg/kg cohorts Pharmacokinetic modeling and simulation indicated that an 80 mg fixed dose provides similar exposure to the 1.0 mg/kg dose, where treatment with NTLA-2001 resulted in 93% mean and 98% maximum serum TTR reduction by day 28 Intellia...

  14. Show article details.

    Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose

    GlobeNewswire – 7:30 AM ET 06/24/2022

    CAMBRIDGE, Mass. and TARRYTOWN, N.Y., June 24, 2022 -- Intellia Therapeutics, Inc. (NTLA) and Regeneron Pharmaceuticals, Inc. (REGN) today announced additional positive interim data from an ongoing Phase 1 study of their lead investigational in vivo genome editing candidate, NTLA-2001, which is being developed as a single-dose treatment for transthyretin amyloidosis.

  15. Show article details.

    BMO Initiates Coverage On This Gene Editing Spearhead

    Benzinga – 2:31 PM ET 06/17/2022

    BMO Initiates Coverage On This Gene Editing Spearhead

  16. Show article details.

    Benzinga's Top Ratings Upgrades, Downgrades For June 17, 2022

    Benzinga – 11:10 AM ET 06/17/2022

    TD Securities upgraded the previous rating for AT&T Inc from Hold to Buy. B of A Securities upgraded the previous rating for The AZEK Co Inc from Neutral to Buy. Baird upgraded the previous rating for M&T Bank Corp from Neutral to Outperform. For Fifth Third Bancorp, Baird upgraded the previous rating of Neutral to Outperform.

  17. Show article details.

    Analyst Ratings for Intellia Therapeutics

    Benzinga – 11:11 AM ET 06/16/2022

    Over the past 3 months, 7 analysts have published their opinion on Intellia Therapeutics stock. These 7 analysts have an average price target of $113.29 versus the current price of Intellia Therapeutics at $38.98, implying upside. Below is a summary of how these 7 analysts rated Intellia Therapeutics over the past 3 months.

  18. Show article details.

    Benzinga's Top Ratings Upgrades, Downgrades For June 16, 2022

    Benzinga – 10:10 AM ET 06/16/2022

    According to Loop Capital, the prior rating for Armstrong World Industries Inc was changed from Hold to Buy. B. Riley Securities upgraded the previous rating for Apple Hospitality REIT Inc from Neutral to Buy. According to Deutsche Bank, the prior rating for Republic Services Inc was changed from Hold to Buy.

  19. Show article details.

    Stocks That Hit 52-Week Lows On Monday

    Benzinga – 12:18 PM ET 06/13/2022

      During Monday's trading, 1214 companies set new 52-week lows. On Monday, the following stocks broke to new 52-week lows: Be sure to monitor Benzinga for the news traders need!

  20. Show article details.

    Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the International Liver Congress™ 2022

    GlobeNewswire – 7:30 AM ET 06/08/2022

    CAMBRIDGE, Mass., June 08, 2022 -- Intellia Therapeutics, Inc. (NTLA), a leading genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced that interim clinical data from the Phase 1 study of NTLA-2001, an investigational therapy in development for the treatment of transthyretin amyloidosis, will be shared in an oral presentation ...

Page:

Today's and Upcoming Events

  • Nov
    02

    NTLA to announce Q3 earnings (Unconfirmed)

Past Events (last 90 days)

  • Aug
    04

    NTLA announced Q2 earnings.

Data provided by Thomson Reuters © 2022

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.